ClinicalTrials.gg
RecruitingNCT06744361KETOHCAUpdated Dec 20, 2024

Ketamine Sedation As Neuroprotective Agent Following Out-of-hospital Cardiac Arrest

A Phase 2 interventional study of esketamine hydrochloride and propofol in Out-of-hospital Cardiac Arrest (OHCA), sponsored by Christian Hassager. Recruiting at 2 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-20.

Sponsored by Christian Hassager · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
282
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Out-of-Hospital Cardiac Arrest with a site in Denmark — 7 open to participants now, 8 under way, 2 of them phase 3. Out-of-Hospital Cardiac Arrest · Denmark.

Planned enrollment
17th of 26
282 · median 376
Started
2024
the only one that year
Phase 2
4 of 38
1 open now
Registered
36th of 38
by date
Lead sponsor
4 of 38
Christian Hassager

Among the 38 studies in Out-of-Hospital Cardiac Arrest with a site in Denmark, this one is the 17th largest by planned enrollment of the 26 interventional ones that give a count, is the only one that started in 2024, is one of 4 in phase 2, and was the 36th registered.

Out-of-Hospital Cardiac Arrest

314 studies on the registry are indexed under Out-of-Hospital Cardiac Arrest; 93 are open to participants now.

Browse Out-of-Hospital Cardiac Arrest studies →

Open to participants now

7 of the 38 studies in Out-of-Hospital Cardiac Arrest with a site in Denmark are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 66 Out-of-Hospital Cardiac Arrest studies recruiting now, 46 (70%) set no upper age limit and 13 (20%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Out-of-Hospital Cardiac Arrest with a site in Denmark, or all of them as a file.
02

Study summary

OHCA is a critical medical emergency with significant mortality and morbidity primarily due to hypoxic-ischemic brain injury (HIBI). Despite advances in resuscitation techniques, the neurological outcomes for survivors remain poor. Current post-resuscitation practices lack specific neuroprotective strategies. Ketamine, an N-Methyl-D-Aspartate (NMDA) receptor antagonist, has shown potential neuroprotective properties in preclinical and clinical studies due to its ability to inhibit excitotoxicity and reduce neuronal apoptosis. This trial hypothesizes that ketamine, when used for sedation in OHCA patients, may offer superior neuroprotective benefits compared to the commonly used sedative propofol. By comparing the effects of ketamine and propofol on neuronal damage markers and long-term neurological outcomes, this study aims to identify a potentially effective intervention to improve the prognosis of OHCA patients.

03

Conditions studied

  • Out-of-hospital Cardiac Arrest (OHCA)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (age ≥18 years) AND
  • resuscitated OHCA of presumed cardiac cause with a shockable first recorded heart rhythm AND
  • mean arterial pressure (MAP) >40 mmHg AND
  • a decision to perform prehospital intubation.

Exclusion criteria

Exclusion Criteria:

  • Advanced life support termination-of-resuscitation (TOR) criteria met
  • Systolic blood pressure >190 mmHg
  • Known allergy to ketamine or propofol
  • Chronic diseases making 180-day survival unlikely
  • Body temperature \<30° C.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
282 participants (estimated)

Study arms

  • Experimental
    S-ketamin

    Intravenous or intraosseous bolus administration at a minimum of 0.5 mg/kg of esketamine

    Drug: esketamine hydrochloride

  • Active comparator
    Propofol

    Prehospital intravenous or intraosseous bolus administration of a minimum dose of 0.25 mg/kg propofol

    Drug: propofol

Interventions

  • DrugEsketamineStudies of EsketamineEsketamine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Prehospital intravenous or intraosseous bolus administration at a minimum of 0.5 mg/kg of esketamine

  • Prehospital intravenous or intraosseous bolus administration at a minimum dose of 0.25 mg/kg propofol

06

What researchers measure

Primary outcomes

  1. Neuron-specific enolase (NSE) measured 48 hours after OHCA

    To determine the neuroprotective efficacy of ketamine compared with propofol administered as part of sedation for intubation after initial resuscitation from OHCA

    Time frame: 48 hours after OHCA

Secondary outcomes

  1. Death from any cause

    Death from any cause 180 days after cardiac arrest

    Time frame: 180 days after cardiac arrest

  2. Neurological outcome: modified Rankin Score (mRS)

    Neurological outcome by and modified Rankin Score (mRS). Meassured from 0 to 6, where 0 is no symptoms.

    Time frame: At 2 weeks (at discharge)

  3. Neurological outcome: Cerebral Performance Categories (CPC)

    Neurological outcome by Cerebral Performance Categories (CPC) meassured fra 1-5 (a score of 1 is normal/good cerebral function).

    Time frame: At 2 weeks (at discharge)

  4. Neurological outcome: modified Rankin Score (mRS)

    Neurological outcome by and modified Rankin Score (mRS). Meassured from 0 to 6, where 0 is no symptoms.

    Time frame: At 180 days after OHCA.

  5. Neurological outcome: modified Rankin Score (mRS)

    Neurological outcome by and modified Rankin Score (mRS). Meassured from 0 to 6, where 0 is no symptoms.

    Time frame: At 240 days after OHCA.

  6. Neurological outcome: Cerebral Performance Categories (CPC)

    Neurological outcome by Cerebral Performance Categories (CPC) meassured fra 1-5 (a score of 1 is normal/good cerebral function).

    Time frame: At 180 days after OHCA.

  7. Neurological outcome: Cerebral Performance Categories (CPC)

    Neurological outcome by Cerebral Performance Categories (CPC) meassured fra 1-5 (a score of 1 is normal/good cerebral function).

    Time frame: At 240 days after OHCA.

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Sep 2027, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2024
First posted
Dec 20, 2024
StartActual
Dec 12, 2024
Primary completionEst.
Sep 1, 2027
CompletionEst.
Sep 1, 2027
Last update
Dec 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06744361
Lead sponsor
Christian Hassager
Responsible party
Christian Hassager (Chief Physician, Rigshospitalet, Denmark) — Sponsor-investigator
First posted
Dec 20, 2024
Start date
Dec 12, 2024
Primary completion
Sep 1, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Dec 20, 2024

Study contacts

Salma Charabi, MD
Contact
salma.charabi@regionh.dk
35450572

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esketamine

Start the discussion